Abigail Brooks

Newly published phase 2b RELIEVE UCCD data show strong 14 week results for duvakitug in ulcerative colitis and Crohn disease.

ACOG updated HIV screening and prevention guidance, recommending opt-out lifetime HIV testing and stronger PrEP counseling and prescribing.

A new study links semaglutide and tirzepatide to fewer alcohol-related hospitalizations in adults with AUD and diabetes or obesity.

Plozasiran cut triglycerides up to 81% and reduced acute pancreatitis events in phase 3 SHASTA-3, SHASTA-4 trials for severe hypertriglyceridemia.

The US FDA Fast Track status advances remlifanserin for Alzheimer disease psychosis, with phase 2 RADIANT data expected in fall 2026.

Topline TRIUMPH-2 and TRIUMPH-3 results showed retatrutide reduced weight by up to 20.8% in adults with type 2 diabetes and 22.6% in adults with CVD.

FDA cleared Roche’s cobas BV/CV assay to detect bacterial vaginosis and Candida vaginitis from a single vaginal swab sample.

The approval makes MannKind Corporation's furosemide injection the first and only autoinjector delivering SC furosemide with IV-equivalent exposure.

This World Hepatitis Day, 3 expert hepatologists discuss bepirovirsen's functional cure data and weigh primary care against specialized centers for delivering this treatment.

FDA clearance adds a noninvasive AI-based test for elevated pulmonary capillary wedge pressure to the CorVista System diagnostic platform.